$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

$tnxp Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416085821 Filed on March 03, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.340M	$3.910M	$2.970M
YoY Change	16.38%	21.05%	33.78%
% of Gross Profit
Research & Development	$10.67M	$9.490M	$10.31M
YoY Change	56.25%	64.19%	97.7%
% of Gross Profit
Depreciation & Amortization	$57.00K	$70.00K	$40.00K
YoY Change	159.09%	250.0%	300.0%
% of Gross Profit
Operating Expenses	$14.01M	$13.40M	$13.28M
YoY Change	44.53%	48.89%	78.64%
Operating Profit		-$13.40M	-$13.28M
YoY Change		48.84%	78.64%
Interest Expense	$40.00K	$40.00K	$30.00K
YoY Change	100.0%	100.0%	50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.98M	-$13.36M	-$13.25M
YoY Change	44.42%	48.61%	78.57%
Income Tax
% Of Pretax Income
Net Earnings	-$13.98M	-$13.36M	-$13.25M
YoY Change	44.41%	48.63%	78.6%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$699.0M	-$668.0M	-$662.5M
COMMON SHARES
Basic Shares Outstanding	18.87M shares	18.83M shares	18.83M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.50M	$43.00M	$55.00M
YoY Change	-52.75%	12.57%	19.05%
Cash & Equivalents	$8.427M	$19.18M	$33.01M
Short-Term Investments	$19.10M	$23.80M	$22.00M
Other Short-Term Assets	$3.200M	$3.300M	$2.100M
YoY Change	77.78%	266.67%	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$30.65M	$46.36M	$57.19M
YoY Change	-48.91%	18.76%	21.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$383.0K	$350.0K	$327.0K
YoY Change	25.16%	6.71%	63.5%
Goodwill
YoY Change
Intangibles	$120.0K	$120.0K	$120.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$692.0K	$659.0K	$636.0K
YoY Change	38.4%	30.24%	48.6%
TOTAL ASSETS
Total Short-Term Assets	$30.65M	$46.36M	$57.19M
Total Long-Term Assets	$692.0K	$659.0K	$636.0K
Total Assets	$31.35M	$47.02M	$57.83M
YoY Change	-48.19%	18.91%	22.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.067M	$3.049M	$2.422M
YoY Change	3.35%	105.04%	-1.06%
Accrued Expenses	$1.844M	$3.601M	$2.675M
YoY Change	22.93%	90.03%	155.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.911M	$6.650M	$5.097M
YoY Change	11.74%	96.63%	45.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.911M	$6.650M	$5.097M
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
Total Liabilities	$4.008M	$6.756M	$5.174M
YoY Change	11.33%	95.83%	45.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.4M	-$102.4M	-$89.04M
YoY Change		88.43%	96.31%
Common Stock		$142.7M	$141.7M
YoY Change		57.77%	58.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.30M	$40.26M	$52.65M
YoY Change
Total Liabilities & Shareholders Equity	$31.30M	$47.02M	$57.83M
YoY Change	-48.26%	18.91%	22.18%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	-$13.98M	-$13.36M	-$13.25M
YoY Change	44.41%	48.63%	78.6%
Depreciation, Depletion And Amortization	$57.00K	$70.00K	$40.00K
YoY Change	159.09%	250.0%	300.0%
Cash From Operating Activities	-$15.49M	-$11.91M	-$12.33M
YoY Change	71.16%	44.89%	153.7%
INVESTING ACTIVITIES
Capital Expenditures	$65.00K	-$50.00K	-$40.00K
YoY Change		-61.54%	-73.33%
Acquisitions
YoY Change
Other Investing Activities	$4.780M	-$1.870M	-$22.06M
YoY Change
Cash From Investing Activities	$4.720M	-$1.920M	-$22.10M
YoY Change		1500.0%	13712.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$16.20M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	18.69M
YoY Change	-100.0%	-100.0%	153.6%
NET CHANGE
Cash From Operating Activities	-15.49M	-11.91M	-12.33M
Cash From Investing Activities	4.720M	-1.920M	-22.10M
Cash From Financing Activities	0.000	0.000	18.69M
Net Change In Cash	-10.77M	-13.83M	-15.74M
YoY Change	-153.85%	72.23%	-769.79%
FREE CASH FLOW
Cash From Operating Activities	-$15.49M	-$11.91M	-$12.33M
Capital Expenditures	$65.00K	-$50.00K	-$40.00K
Free Cash Flow	-$15.56M	-$11.86M	-$12.29M
YoY Change	71.88%	46.6%	160.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	Tonix Pharmaceuticals Holding Corp.
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001430306
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	107689550	USD
CY2015	dei	Trading Symbol TradingSymbol	TNXP
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18873264	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3343000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	852000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	46359000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	39036000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	132000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	133000	USD
CY2015Q4	us-gaap	Assets Assets	47018000	USD
CY2014Q4	us-gaap	Assets Assets	39542000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3049000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1487000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3601000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1895000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6650000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3382000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	106000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	68000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	6756000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	3450000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	19000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	142658000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90423000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102398000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54344000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	40262000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	36092000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47018000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39542000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	350000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	328000	USD
CY2015Q4	us-gaap	Security Deposit SecurityDeposit	57000	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	45000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35504000	USD
CY2015	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	108000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-48054000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-27656000	USD
CY2014	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	40000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4650000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12658000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-48162000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.86
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16791059	shares
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18617000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9039000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-27616000	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.77
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9985515	shares
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1	2680000	shares
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-45303000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-14693000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2751000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000	USD
CY2015Q1	tnxp	Warrants Exercise Price WarrantsExercisePrice	20.00
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6238000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-10888000	USD
CY2013	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-10884000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.37
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3231311	shares
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-3000	USD
CY2015	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	11000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28643000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27613000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-8000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-19000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48073000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2015	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	27000	USD
CY2015	tnxp	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	29000000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10885000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	160000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	4389000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	USD
CY2015	tnxp	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	18685000	USD
CY2015	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants Transaction StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsTransaction	9000	USD
CY2015	us-gaap	Depreciation Depreciation	161000	USD
CY2014	us-gaap	Depreciation Depreciation	36000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	4389000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	3088000	USD
CY2015	tnxp	Issuance Of Common Stock To Intellectual Property IssuanceOfCommonStockToIntellectualProperty	0	USD
CY2014	tnxp	Issuance Of Common Stock To Intellectual Property IssuanceOfCommonStockToIntellectualProperty	608000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2524000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	423000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1583000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	728000	USD
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1874000	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	729000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-42528000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22840000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24171000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-392000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5661000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	47694000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	53217000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-4000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-3000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19175000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38184000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19009000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29982000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8202000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47685000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47836000	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	160000	USD
CY2014	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2014	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	45000	USD
CY2015	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	0	USD
CY2014	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	73000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	120000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2015	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.19	pure
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2015	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2014	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	280000	USD
CY2015Q4	tnxp	Working Capital Amount WorkingCapitalAmount	39700000	USD
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15384000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	8457000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4100000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3100000	USD
CY2015Q1	tnxp	Warrants Expired Number Of Warrants WarrantsExpiredNumberOfWarrants	14538	shares
CY2015	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	7649000	USD
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	23841000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	31490000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18831669	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10805220	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18831669	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10805220	shares
CY2015Q4	tnxp	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	17595	shares
CY2014Q4	tnxp	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	13978	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.25
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	959000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1717000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	3053000	USD
CY2013	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants Transaction StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsTransaction	307000	USD
CY2014	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants Transaction StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsTransaction	5661000	USD
CY2013	tnxp	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	10042000	USD
CY2014	tnxp	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	40654000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	412000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	180000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	84000	USD
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	2246000	USD
CY2014Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	604000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1128000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	868000	USD
CY2013	tnxp	Description Of Option Granted Under Underwriting Agreement DescriptionOfOptionGrantedUnderUnderwritingAgreement	the Company also granted the Third Underwriters an option for a period of 45 days to purchase up to (i) 402,000 additional Units or (ii) 402,000 additional shares of common stock and/or additional Warrants to purchase up to 402,000 shares of common stock, on the same terms, to cover over-allotments, if any.
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	6512000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35000	USD
CY2014	tnxp	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	7182000	USD
CY2014	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	608000	USD
CY2013	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants Transaction One StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsTransactionOne	3761000	USD
CY2013	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants Transaction Two StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsTransactionTwo	560000	USD
CY2013	tnxp	Issuance Of Common Stock To Intellectual Property IssuanceOfCommonStockToIntellectualProperty	0	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	204000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-60000	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3000	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	51000	USD
CY2013	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants On Cash Less Basis StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsOnCashLessBasis	0	USD
CY2014	tnxp	Stock Issued During Period Value In Exchange For Exercise Of Warrants On Cash Less Basis StockIssuedDuringPeriodValueInExchangeForExerciseOfWarrantsOnCashLessBasis	0	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	423000	USD
CY2013	us-gaap	Depreciation Depreciation	17000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1717000	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	856000	USD
CY2013	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2015	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	54000	USD
CY2014	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	55000	USD
CY2013	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-7000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8517000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2013	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-15000	USD
CY2015	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2014	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2013	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	280000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4628000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10042000	USD
CY2013	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14950000	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-1000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6417000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1785000	USD
CY2013	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2013	tnxp	Description Of Unit DescriptionOfUnit	Each Unit consisted of (i) one share of common stock and (ii) one Series A Warrant (the Warrants) to purchase one share of common stock.
CY2015Q4	tnxp	Shares Outstanding Before Reverse Stock Split SharesOutstandingBeforeReverseStockSplit	43182599	shares
CY2015	us-gaap	Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares	2159159	shares
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	41000000	USD
CY2015	tnxp	Reverse Stock Split Effective Date ReverseStockSplitEffectiveDate	2013-05-01
CY2015	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	20-for-1
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	tnxp	Warrants Issued During Period To Purchase Common Stock WarrantsIssuedDuringPeriodToPurchaseCommonStock	10800	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.00
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	tnxp	Warrants Exercised Number Of Warrants WarrantsExercisedNumberOfWarrants	3185	shares
CY2014	tnxp	Stock Issued During Period Exercise Price Acquisitions StockIssuedDuringPeriodExercisePriceAcquisitions	12.15
CY2014	tnxp	Warrants Exercised Number Of Warrants WarrantsExercisedNumberOfWarrants	48240	shares
CY2015	us-gaap	Operating Expenses OperatingExpenses	48162000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	27656000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	10888000	USD
CY2013	tnxp	Stock Issued During Period Exercise Price Warrants Exercised StockIssuedDuringPeriodExercisePriceWarrantsExercised	4.25
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	96000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	36000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4710000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	tnxp	Stock Issued During Period Exercise Price Warrants Exercised StockIssuedDuringPeriodExercisePriceWarrantsExercised	4.25
CY2015	tnxp	Stock Issued During Period Exercise Price Warrants Exercised StockIssuedDuringPeriodExercisePriceWarrantsExercised	4.25
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	132000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	132000	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	351000	USD
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	240000	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	179000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	172000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	530000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0202	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9996	pure
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1729217	shares
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12923000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-48054000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-27616000	USD
CY2013	tnxp	Warrants Expired Number Of Warrants WarrantsExpiredNumberOfWarrants	3185	shares
CY2014Q1	tnxp	Warrants Expired Number Of Warrants WarrantsExpiredNumberOfWarrants	750	shares
CY2014Q1	tnxp	Warrants Exercise Price WarrantsExercisePrice	20.00
CY2014	tnxp	Warrants Expired Number Of Warrants WarrantsExpiredNumberOfWarrants	48240	shares
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.350	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.350	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.006	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.102	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.002	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.003	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.046	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.220	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.327	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.240	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.019	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11645000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11320000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3186000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1336000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	388000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	200000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	224000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	364000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15449000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13226000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15449000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13226000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	670000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	683000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	607000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	181000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2141000	USD
CY2015Q4	us-gaap	Other Commitment OtherCommitment	20100000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	112000	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	52000	USD
CY2015Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	6000	USD
CY2014Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	17000	USD
CY2015Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	34000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9696000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11784000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13280000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-13402000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-9681000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-11763000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-13250000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-13360000	USD
CY2014Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2019-04-30
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5169000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6049000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7434000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9004000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5164000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6044000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-7419000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-8989000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.83
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	300000	USD
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	300000	USD
CY2014Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	200000	USD
CY2014Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	100000	USD
CY2015	us-gaap	Reimbursement Revenue ReimbursementRevenue	53000	USD
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Risks and uncertainties</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's primary efforts are devoted to conducting research and development for the treatment of disorders of the central nervous system. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated revenues and there is no assurance that if the Food and Drug Administration (“FDA”) approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be FDA-approved or commercially viable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2015, the Company had working capital of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39.7</font> million, after raising $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">47.7</font> million through the sale of common stock during 2015. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 12 months. The Company expects that cash used in operations for research and development will increase significantly over the next several years. In the event the funding obtained is not sufficient to complete the development and commercialization of its current product candidates, the Company intends to raise additional funds through equity or debt financing. If the Company is unsuccessful in raising additional financing, it will need to reduce costs and operations in the future.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	tnxp	Contract Related Assets Current ContractRelatedAssetsCurrent	2826000	USD
CY2014Q4	tnxp	Contract Related Assets Current ContractRelatedAssetsCurrent	519000	USD
CY2015Q4	tnxp	Prepaid Professional Fee And Other PrepaidProfessionalFeeAndOther	517000	USD
CY2014Q4	tnxp	Prepaid Professional Fee And Other PrepaidProfessionalFeeAndOther	333000	USD
CY2015Q4	us-gaap	Mortgage Backed Securities Available For Sale Fair Value Disclosure MortgageBackedSecuritiesAvailableForSaleFairValueDisclosure	23841000	USD
CY2014Q4	us-gaap	Mortgage Backed Securities Available For Sale Fair Value Disclosure MortgageBackedSecuritiesAvailableForSaleFairValueDisclosure	0	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	42000	shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.74
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.20
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.83
CY2013	tnxp	Warrants Expiration Period WarrantsExpirationPeriod	P5Y
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-502000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10382000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10884000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.105	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.067	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.378	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><u>Use of estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets, assumptions used in the fair value of stock-based compensation and other equity instruments, and the percent of completion of research and development contracts.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4100000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3800000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2200000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	651357	shares

Files In Submission

Name	View Source	Status
0001144204-16-085821-index-headers.html	Edgar Link	pending
0001144204-16-085821-index.html	Edgar Link	pending
0001144204-16-085821.txt	Edgar Link	pending
0001144204-16-085821-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnxp-20151231.xml	Edgar Link	completed
tnxp-20151231.xsd	Edgar Link	pending
tnxp-20151231_cal.xml	Edgar Link	unprocessable
tnxp-20151231_def.xml	Edgar Link	unprocessable
tnxp-20151231_lab.xml	Edgar Link	unprocessable
tnxp-20151231_pre.xml	Edgar Link	unprocessable
tpg42.jpg	Edgar Link	pending
v432316_10k.htm	Edgar Link	pending
v432316_ex21-01.htm	Edgar Link	pending
v432316_ex23-01.htm	Edgar Link	pending
v432316_ex31-01.htm	Edgar Link	pending
v432316_ex31-02.htm	Edgar Link	pending
v432316_ex32-01.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2016 Q1 Form 10-K Financial Statement

#000114420416085821 Filed on March 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2016 Q1 Form 10-K Financial Statement

#000114420416085821 Filed on March 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp